



Oregon Prescription Drug Affordability Board (PDAB) Regular Meeting
Wednesday, August 20, 2025
Minutes approved by the board on Oct. 15, 2025

Web link to the meeting video: <https://youtu.be/wAl1u10eAM4>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20250820-PDAB-document-package.pdf>

Call to order: Chair Shelley Bailey called the meeting to order at 9:00 a.m. and roll was called.

Board members present: Chair Shelley Bailey, Dan Hartung, Dan Kennedy, Chris Laman, John Murray

Absent: Vice Chair Amy Burns, Lauri Hoagland

Declaration of conflict of interest, meetings with entities or individuals related to board activities, or testifying before the Legislature: John Murray provided a statement. View at video minute [00:00:38](#).

Approval of board minutes: Chair Bailey asked for a motion and second to approve the board minutes as shown on [Pages 3-8](#) of the agenda materials. Dan Kennedy made a motion to approve the minutes and John Murray provided a second. View the vote at video minute [00:01:44](#).

MOTION to approve the July 16, 2025, minutes

Board Vote:

Yes: Dan Hartung, Dan Kennedy, Chris Laman, John Murray, Chair Shelley Bailey

No: None

Absent: Vice Chair Amy Burns, Lauri Hoagland

Motion passed 5-0

Executive session for legal advice pursuant to ORS 192.660(2)(f): The board adjourned to executive session. No decisions were made in closed session. View at video minute [00:02:48](#) The board returned to open session and called roll to confirm a board quorum. View at video minutes [00:03:45](#).

PDAB program update: Cortnee Whitlock, PDAB senior policy analyst, provided a program update. View the video at minute [00:04:12](#).

General public comment: Chair Bailey called on the people who signed up in advance to speak to the board: Lorren Sandt, Caring Ambassadors, Ranier Simons, CANN, Tiffany Westrich-Robertson, EACH/PIC Coalition, Dharia McGrew, PhRMA, Derek Flowers, Value of Care Coalition, Silas Martin, Johnson and Johnson, Jessica McBride, OCAP.

The board received 12 written comments, which are posted on the [PDAB website](#). View the speakers at video minute [00:06:00](#) and [00:30:14](#).

Board review of methodology for drug reviews and scoring rubric and worksheet: Cortnee Whitlock, senior policy analyst, led the board in a discussion about the drug review process. View the slide presentation on [Pages 6-17](#). View the discussion at video minute [00:23:43](#).

Round 2 drug reviews: The board began discussions about drug reviews for Trelegy, Eliquis, Xarelto, Cosentyx, and Creon.



Drug review for Trelegy - Antiasthmatic and bronchodilator: View the Trelegy report on [Pages 18-46](#) posted on the PDAB website. View the discussion at video minute [01:27:34](#). View the public comment for Trelegy at [01:27:47](#).

Drug review for Eliquis – Anticoagulants: View the Eliquis report on [Page 48-79](#). View the discussion at video minute [02:06:26](#). View the public comment for Eliquis at [02:06:39](#).

Drug review for Xarelto – Anticoagulants: View the Xarelto report on [Pages 80-110](#). View the discussion at video minute [02:24:19](#). View the public comment for Xarelto at [02:24:19](#).

Drug review for Cosentyx - Dermatological: View the Cosentyx report on [Page 111-144](#). View the discussion at video minute [02:43:33](#). View the public comment for Cosentyx at video minute [02:55:14](#).

Drug review for Creon –Digestive Aids: View the Creon report on [Pages 145 - 175](#). View the discussion at video minute [02:58:51](#). View the public comment for Creon at video minute [02:59:08](#).

Drug review public comment periods: Chair Bailey announced public comment periods for people who signed up in advance to speak specifically about the drugs under review. The chair also read the list of letters received regarding the drugs under review. See table below for list of public comment speakers.

Announcements: Chair Bailey announced the next meeting will be Sept. 17, 2025, at 8 a.m. View at video minute [03:10:52](#).

Adjournment: Chair Bailey adjourned the meeting at 11:30 a.m. with all board members in agreement. View at minute [03:11:01](#).



Table of public comment letters and speakers for Group 2 drugs

Name of speaker	Association to drug under review	Drug	Format	Date	Exhibit website link
Harmeet Dhillon	GSK	Trelegy	Letter	5/21/2025	Exhibit A
Linda Nelson	Oregon Coalition for Affordability Prescriptions	Trelegy	Letter	5/21/2025	Exhibit B
Molly Burich	GSK	Trelegy	Letter	8/15/2025	Exhibit C
Tom Corbridge	GSK	Trelegy	Speaker	8/20/2025	Exhibit D
Anne Murray	Bristol Myers Squibb	Eliquis	Letter Speaker Letter Letter	5/21/2025 5/21/2025 7/13/2025 8/18/2025	Exhibit E Exhibit F Exhibit G Exhibit H
Sarah Hoffman	Partnership to Advance Cardiovascular Health	Eliquis	Letter	5/21/2025	Exhibit I
Sue Koob	Preventive Cardiovascular Nurses Association	Eliquis	Letter	7/14/2025	Exhibit J
John Mullin and board members	Oregon Coalition for Affordable Prescriptions	Eliquis	Letter	8/15/2025	Exhibit K
Sarah Hoffman	Partnership to Advance Cardiovascular Health	Xarelto	Letter	5/21/25	Exhibit L
Silas Martin	Johnson & Johnson	Xarelto	Speaker	5/21/25	Exhibit M
Michael Valenta	Johnson & Johnson	Xarelto	Letters	3/30/25 6/16/25 8/14/25	Exhibit N Exhibit O Exhibit P
Sue Koob	Preventive Cardiovascular Nurses Association	Xarelto	Letter	7/14/25	Exhibit Q
Lisa Pulver	Johnson & Johnson	Xarelto	Speaker	8/20/25	Exhibit R
Courtney Piron	Novartis	Cosentyx	Letters	5/1/2025 8/12/2025	Exhibit S Exhibit T
Gabrielle Draper	Derma Care Access Network	Cosentyx	Letter	8/17/2025	Exhibit U
Kim Sanders	OHSU	Cosentyx	Letter	8/17/2025	Exhibit V
Tiffany Westrich-Robertson	Patient living with arthritis and on Cosentyx for four years	Cosentyx	Speaker	8/20/2025	Exhibit W
Albert Faro et al	Cystic Fibrosis Foundation	Creon	Letter	5/21/2025	Exhibit X
Lindsay Silva	Mother/primary care giver to someone living with Cystic Fibrosis	Creon	Speaker	5/21/2025	Exhibit Y